A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer

Ward, S.; Morris, E.; Bansback, N.; Calvert, N.; Crellin, A.; Forman, D.; Larvin, Michael; Radstone, D.

Publication

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer

Ward, S.; Morris, E.; Bansback, N.; Calvert, N.; Crellin, A.; Forman, D.; Larvin, Michael; Radstone, D.

Date

2001

Abstract

Pancreatic cancer is the eighth most common cancer in the UK and the sixth most common cause of cancer death; in 1998, 3198 men and 3364 women died from this condition. In an average health authority with a population of 500,000, there would be approximately 60 new cases of pancreatic cancer per year, based on the age and sex distribution of England and Wales. Over 75% of these patients are over 65 years of age.

Description

peer-reviewed

Publisher

NIHR Journals Library

Citation

Health Technology Assessment;5 (24)

A rapid and systematic review of the clinical effectiveness and cost-effectiveness of gemcitabine for the treatment of pancreatic cancer

Date

Abstract

Supervisor

Description

Publisher

Citation

Collections

Files

Keywords

ULRR Identifiers

Funding code

Funding Information

Sustainable Development Goals

External Link

License

Embedded videos